Novavax Inc NVAX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:43 PM EST
239.02quote price arrow down-0.92 (-0.38%)
Volume
10,870
Close
239.94quote price arrow down-3.29 (-1.35%)
Volume
1,582,049
52 week range
6.77 - 331.68

...

Loading . . .

KEY STATS

  • Open243.90
  • Day High247.94
  • Day Low234.21
  • Prev Close243.23
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low6.77
  • 52 Week Low Date03/16/20
  • Market Cap15.275B
  • Shares Out63.66M
  • 10 Day Average Volume3.14M
  • Dividend-
  • Dividend Yield-
  • Beta1.57
  • 1 Year % Change2,838.64

RATIOS/PROFITABILITY

  • EPS (TTM)-5.22
  • P/E (TTM)-45.98
  • Fwd P/E (NTM)21.60
  • EBITDA (MRQ)-262.448M
  • ROE (MRQ)-829.23%
  • Revenue (MRQ)204.76M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-133.10%
  • Debt To Equity (MRQ)143.88%

EVENTS

  • Earnings Date03/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

QUOTE FINDER

Related Video

VIDEO2:3302:33
Novavax interim data shows its vaccine is 89% effective in U.K. trial

Profile

MORE
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates...
James Young Ph.D.
Chairman
Stanley Erck
President
Rick Crowley
Chief Operating Officer
Gregory Covino
Chief Financial Officer
Ben Machielse
Executive Vice President
Address
21 Firstfield Rd
Gaithersburg, MD
20878-1757
United States